[Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease].

Autor: Sekkach Y; Département de médecine interne-B, hôpital Militaire d'Instruction Med-V, Rabat, Maroc. sekkach@hotmail.com, Elqatni M, Khattabi AE, Fatihi J, Hammi S, Badaoui M, Elomri N, Mekouar F, Amezyane T, Abouzahir A, Ghafir D
Jazyk: francouzština
Zdroj: Presse medicale (Paris, France : 1983) [Presse Med] 2011 Jul-Aug; Vol. 40 (7-8), pp. e333-7. Date of Electronic Publication: 2011 May 07.
DOI: 10.1016/j.lpm.2011.03.012
Abstrakt: Introduction: The pathogenesis of Still's disease is best elucidated for the better recognition of the involvement of Many pro-inflammatory cytokines in the genesis of this condition. Publications have reported the contribution beneficial for certain biotherapeutics, such as anti-TNFa, the anti-CD20 or antagonists of interleukine1 (IL-1) tested successfully in the treatment of systemic Juvenile idiopathic arthritis (Still's disease the child), the tocilizumab is a humanized monoclonal antibody directed against the receptor for interleukin-6 and is beginning to be reported as effective in some refractory cases of Still's disease in adults.
Patients: We report two young patients with Still's disease in adults with refractory early and prolonged remission after the first infusion tocilizumab.
Conclusion: The tocilizumab can be used in patients MSA with refractory after failure or intolerance conventional treatments.
(Copyright © 2011 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: